Market News & Trends
Inovio Pharmaceutical’s DNA Vaccine for Zika Virus Induces Robust Immune Responses
Inovio Pharmaceuticals, Inc. recently announced that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential…
Emergent BioSolutions’ Auto-Injector Platform Selected by US Department of Defense & Battelle
Emergent BioSolutions Inc. recently announced that Emergard, the company’s ruggedized, military-grade auto-injector platform, has been selected by the US Department of Defense (DoD) and Battelle…
Galapagos Starts SAPHIRA Phase II Study With GLPG1837 in Cystic Fibrosis Patients
Galapagos NV recently announced the first dosing in its Phase II exploratory program of GLPG1837 in patients with cystic fibrosis (CF). GLPG1837 is a candidate…
ICON Selected by Genomics England to Support Largest Genome Sequencing Project
ICON plc recently announced it has been selected by Genomics England as data management partner for the 100,000 Genomes Project. A ground-breaking project announced by…
Biota Commences Dosing in Phase II Trial of Antiviral Therapy
Biota Pharmaceuticals, Inc. recently announced that the first patient has been dosed in a Phase II double-blind, randomized, placebo-controlled trial to evaluate the safety, tolerability…
VBI Vaccines Announces Vaccine Stability Collaboration With GlaxoSmithKline
VBI Vaccines Inc. has entered into a research collaboration with GlaxoSmithKline Biologicals SAto evaluate VBI’s LPV Platform, a proprietary formulation and process that enables the…
ZIOPHARM Announces First Patient Enrolled in Phase I Study; Drug Uses Sleeping Beauty Platform
ZIOPHARM Oncology, Inc. recently announced that the first patient has been enrolled in a Phase I clinical study of its second-generation non-viral CD19-specific chimeric antigen…
BioXcel Expands Into CNS Orphan Disease Therapeutics
BioXcel Corporation recently announced its expansion into CNS Orphan Diseases that require novel treatment solutions for neurological manifestations, including neurodegenerative disorders, motor dysfunction disorders, and…
RedHill Biopharma Announces Collaboration With Germany’s Fraunhofer Institute
RedHill Biopharma Ltd. recently announced a research collaboration with Leipzig-based Fraunhofer Institute for Cell Therapy and Immunology (IZI), a research unit of the Fraunhofer Society…
Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.
Sigmoid Pharma Ltd recently announced it has entered into an agreement to acquire Freund Pharmatec Ltd. Through this acquisition, Sigmoid will acquire 100% ownership of…